Stay updated with the latest developments, partnerships, and milestones from Hong Kong Regen Medtech Limited.
2024
Previous year highlights and announcements.
20
Nov
2024
HKRM Announces Strategic Partnership with Japanese Cell Therapy Pioneer
HKRM has entered into a strategic collaboration agreement with a leading Japanese cell therapy company to co-develop next-generation MSC differentiation protocols for musculoskeletal applications.
Partnership
05
Aug
2024
HKRM PIC/S GMP Facility Passes International Audit
The HKRM manufacturing facility at Hong Kong Science Park has successfully passed an independent international GMP audit, confirming compliance with PIC/S standards recognised by over 50 regulatory authorities worldwide.
Manufacturing
12
Mar
2024
HKRM Establishes R&D Centre at Hong Kong Science Park
Hong Kong Regen Medtech Limited officially opened its research and development centre at 5W Building, Hong Kong Science Park, establishing a state-of-the-art laboratory for stem cell research and manufacturing process development.
Corporate
2023
Earlier announcements and media coverage.
22
Jul
2023
HKSTP Partner Companies HKRM and Cordlife Sign Collaboration Agreement to Advance Stem Cell Therapy
Hong Kong Science and Technology Parks Corporation reported that HKRM and Cordlife Hong Kong Limited announced a collaboration under HKSTP’s MedTech Co-Create programme to co-launch regenerative medicine projects focused on Mesenchymal Stem Cells (MSCs), aiming to advance stem cell therapy and improve public awareness of regenerative medicine.
HKRM Granted First Stem Cell Manufacturer Licence, Plans to Introduce Acute Liver Failure Treatment
Hong Kong Regen Medtech Limited (HKRM) has obtained the city’s first stem cell manufacturer licence, establishing the first government-recognised stem cell production facility. The company plans to introduce a treatment for acute liver failure and expects to supply its products to local public and private hospitals, as well as mainland China and Southeast Asia in the future.
HKRM Granted Government Licence to Become Hong Kong’s First Certified Stem Cell Production Facility, Planning to Launch Treatment for Acute Liver Failure
Hong Kong Regen Medtech (HKRM) has been granted the city’s first stem cell manufacturer licence by the Department of Health. The company is actively promoting clinical research and commercialization of stem cell products, and is planning to launch a treatment for acute liver failure.
科技園夥伴企業獲發全港首個幹細胞生產牌照
香港科技園舉行細胞及基因治療成果展，並公布香港再生醫學取得全港首個幹細胞生產牌照。該牌照符合國際醫藥組織認可的優良製造規範標準，允許公司於科學園營運獲政府認可的生產設施，製造用於臨床試驗的先進療法治療產品。
科技園公布首個公共臍帶血庫臨床進展
香港科技園公司舉行成果展示，介紹全港首間持牌幹細胞生產設施及首個公共臍帶血庫的臨床進展。香港再生醫學（HKRM）獲得全港首個幹細胞生產牌照，可製造用於臨床試驗的先進療法藥物。同時，Mononuclear Therapeutics 營運全港首個公共臍帶血庫，已儲存逾 2,000 份臍帶血單位。
Latest News & Announcements
Stay updated with the latest developments, partnerships, and milestones from Hong Kong Regen Medtech Limited.
2024
Previous year highlights and announcements.
HKRM Announces Strategic Partnership with Japanese Cell Therapy Pioneer
HKRM has entered into a strategic collaboration agreement with a leading Japanese cell therapy company to co-develop next-generation MSC differentiation protocols for musculoskeletal applications.
PartnershipHKRM PIC/S GMP Facility Passes International Audit
The HKRM manufacturing facility at Hong Kong Science Park has successfully passed an independent international GMP audit, confirming compliance with PIC/S standards recognised by over 50 regulatory authorities worldwide.
ManufacturingHKRM Establishes R&D Centre at Hong Kong Science Park
Hong Kong Regen Medtech Limited officially opened its research and development centre at 5W Building, Hong Kong Science Park, establishing a state-of-the-art laboratory for stem cell research and manufacturing process development.
Corporate2023
Earlier announcements and media coverage.
HKSTP Partner Companies HKRM and Cordlife Sign Collaboration Agreement to Advance Stem Cell Therapy
Hong Kong Science and Technology Parks Corporation reported that HKRM and Cordlife Hong Kong Limited announced a collaboration under HKSTP’s MedTech Co-Create programme to co-launch regenerative medicine projects focused on Mesenchymal Stem Cells (MSCs), aiming to advance stem cell therapy and improve public awareness of regenerative medicine.
Media Enquiries
For press enquiries, interview requests, or additional information, please contact our communications team.
联络我们HKRM Granted First Stem Cell Manufacturer Licence, Plans to Introduce Acute Liver Failure Treatment
Hong Kong Regen Medtech Limited (HKRM) has obtained the city’s first stem cell manufacturer licence, establishing the first government-recognised stem cell production facility. The company plans to introduce a treatment for acute liver failure and expects to supply its products to local public and private hospitals, as well as mainland China and Southeast Asia in the future.